Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Mammalian target of rapamycin (mTOR) signaling is crucial for tumor development, regulating cancer cell growth, angiogenesis, and immune response.
• mTOR inhibitors have been investigated in cancer therapy but often face resistance, necessitating combination strategies.
• Emerging evidence suggests mTOR inhibitors can enhance immunotherapy efficacy, despite some immunosuppressive properties.

Purpose of the Study:

• To review different classes of mTOR inhibitors.
• To discuss the effects of mTOR inhibitors on immune cells, particularly CD8+ T cells.
• To provide an overview of preclinical studies combining mTOR inhibitors with immunotherapies.

Main Methods:

• Literature review of mTOR inhibitors and their effects on immune cells.
• Focus on CD8+ T cell responses to mTOR inhibition.
• Analysis of preclinical studies investigating combination therapies.

Main Results:

• mTOR inhibitors can promote memory CD8+ T cell generation, exhibiting immunostimulatory effects.
• These effects present a therapeutic opportunity to enhance antitumor CD8 responses.
• Combination of mTOR inhibitors with immunotherapies shows potential in preclinical settings.

Conclusions:

• mTOR inhibitors represent a valuable therapeutic strategy to boost cancer immunotherapy efficacy.
• Further research into optimizing mTOR inhibitor use, potentially by mitigating immunosuppressive effects, is warranted.
• Targeting mTOR pathways can shift immune responses towards effective antitumor immunity.